Tag: seen-at-their
-
ICU Medical to buy Pfizer’s infusion therapy business
(Reuters) – Medical device maker ICU Medical Inc said it would buy Pfizer Inc's global infusion therapy business, Hospira Infusion Systems, for $1 billion in cash and stock. Pfizer will receive $600 million in cash and nearly $400 million in newly issued shares of ICU Medical common stock, giving the drugmaker a stake of about…
-
ICU Medical to buy Pfizer’s infusion therapy business
(Reuters) – Medical device maker ICU Medical Inc said it would buy Pfizer Inc's global infusion therapy business, Hospira Infusion Systems, for $1 billion in cash and stock. Pfizer will receive $600 million in cash and nearly $400 million in newly issued shares of ICU Medical common stock, giving the drugmaker a stake of about…
-
Polish parliament rejects near-total abortion ban after protests
By Pawel Sobczak and Marcin Goettig WARSAW (Reuters) – Following protests by tens of thousands of women, Polish lawmakers on Thursday rejected plans for a near-total ban on abortion, in a hastily arranged vote that marks the first major domestic setback for the conservative government. The ruling Law and Justice party (PIS) unexpectedly withdrew its…
-
Polish parliament rejects near-total abortion ban after protests
By Pawel Sobczak and Marcin Goettig WARSAW (Reuters) – Following protests by tens of thousands of women, Polish lawmakers on Thursday rejected plans for a near-total ban on abortion, in a hastily arranged vote that marks the first major domestic setback for the conservative government. The ruling Law and Justice party (PIS) unexpectedly withdrew its…
-
Study finds targeted cancer drugs may work in range of tumor types
By Deena Beasley CHICAGO (Reuters) – Early results from a clinical trial of Roche Holding AG cancer drugs released on Saturday suggest some promise in matching treatments based on abnormalities found in a patient's tumor rather than the organ in which the cancer was originally detected. The findings, presented at the annual meeting of the…
-
Roche breast cancer drug Perjeta rejected by NICE
Roche's breast cancer drug Perjeta, or pertuzumab, has been turned down for use on Britain's state health service, making it the latest in a number of pricey new cancer treatments deemed not to offer value for money. The National Institute for Health and Care Excellence (NICE) said in draft guidance on Friday that it could…
-
Roche breast cancer drug Perjeta rejected by NICE
Roche's breast cancer drug Perjeta, or pertuzumab, has been turned down for use on Britain's state health service, making it the latest in a number of pricey new cancer treatments deemed not to offer value for money. The National Institute for Health and Care Excellence (NICE) said in draft guidance on Friday that it could…
-
Yellow fever outbreaks in Africa need action, mass vaccination – WHO
By Stephanie Nebehay GENEVA (Reuters) – Outbreaks of deadly yellow fever in Angola and the Democratic Republic of Congo do not constitute a global health emergency but require stepped-up control measures and mass vaccination, the World Health Organisation (WHO) said on Thursday. “This can be a devastating disease with rapid spread particularly in urban areas,”…
-
What does the world know about rescued Chibok schoolgirl Amina Ali?
The rescue of one of more than 200 Nigerian schoolgirls abducted by the Islamist group Boko Haram from a secondary school in Chibok in northeastern Nigeria two years has thrown global attention onto Amina Ali. President Muhammadu Buhari vowed at a news conference on Thursday that Ali would continue her education and condemned the brutality…
-
Sanofi, Amgen cholesterol drugs win UK backing after price cuts
Two rival cholesterol-lowering injections from Sanofi and Amgen have been recommended by Britain's healthcare cost watchdog after the manufacturers offered special discounts to the country's state-run health service. Sanofi's Praluent, which was developed with Regeneron, and Amgen's Repatha are both so-called PCSK9 medicines that work in a different way to existing cholesterol fighters such as…